NASDAQ · ALVOW
Healthcare · Drug Manufacturers - Specialty & Generic
$0.14
Down-$0.01 (-6.73%)
Updated Nov 5, 2026, 7:06 PM
SID Score
3.3/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · ALVOW
1M range · 8 trading sessions · Daily adjusted prices
Prices through Nov 4, 2026
ALVOW closed at $0.14 after 8 trading sessions, down 66.67% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 4, 2026 | $0.1651 | $0.2101 | $0.14 | $0.14 | 12.2K |
| Nov 3, 2026 | $0.1801 | $0.24 | $0.1501 | $0.1501 | 10.11K |
| Nov 2, 2026 | $0.2951 | $0.2951 | $0.2951 | $0.2951 | 354 |
| Oct 30, 2026 | $0.4499 | $0.4499 | $0.2436 | $0.2436 | 2.29K |
| Oct 28, 2026 | $0.22 | $0.4027 | $0.17 | $0.1865 | 15.73K |
| Oct 27, 2026 | $0.1995 | $0.1995 | $0.1533 | $0.17 | 1.67K |
| Oct 26, 2026 | $0.1999 | $0.20 | $0.1999 | $0.1999 | 1.81K |
| Oct 23, 2026 | $0.4499 | $0.4499 | $0.42 | $0.42 | 1.18K |
The latest Smart Investors Daily articles mentioning ALVOW.
Company
Market Activity
Research & News
ALVOW research
Company profile and research snapshot.
Alvotech is an integrated biopharmaceutical company committed to developing and manufacturing high-quality biosimilar medicines for patients globally. its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases.
Visit company websiteConsensus and target data currently published for this company.
Generated Nov 5, 2026, 7:00 PM
Alvotech shares declined 6.73% today amid growing investor concerns about the company's upcoming earnings report. With negative earnings expected to be announced next week, market sentiment has turned cautious as investors brace for potentially disappointing financial results.
Bottom line: Alvotech's 6.73% decline reflects pre-earnings anxiety as investors prepare for negative financial results next week. The key to recovery will depend on management's ability to demonstrate a credible turnaround strategy or highlight upcoming catalysts that justify continued investment, making next week's earnings call and guidance critically important for the stock's trajectory.
Yahoo · Nov 4, 2026
Alvotech (ALVO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Yahoo · Nov 2, 2026
REYKJAVIK, ICELAND (November 2, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that members of the management team will participate in upcoming investor conferences in November as follows: UBS Global Biopharma Conference in London– fireside chat Tuesday, November 17 at 14:00 GMT (9:00 am ET).2026 Jefferies Global Healthcare Conference in London – presentation
SeekingAlpha · Oct 30, 2026
AbbVie posts strong Q3 growth, Skyrizi sales surge, and 2026 EPS guidance rises. Click for this ABBV earnings update.
Yahoo · Oct 28, 2026
REYKJAVIK, Iceland, Oct. 28, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB) (the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that it will release its financial results for the nine months and third quarter ended September 30, 2026 on Wednesday, November 11, 2026, after the U.S. market close. The Company will also host a webcast with a live Q&A on Thursday, November 12, 2026,
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning ALVOW.
